Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Researchers have designed a new app that can help kids growing up with autism develop basic social skills. The app, called Look At Me, aims to train autistic children to maintain eye contact and convey basic emotions.

  • U. S. Food and Drug Administration granted accelerated approval to palbociclib (IBRANCE, Pfizer, Inc.) for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

    [adsense:336x280:8701650588]

  • A new study has found that high levels of arsenic in drinking water were associated with an "astonishing" 50 per cent drop in breast cancer deaths in Chile. The study presents results of breast cancer mortality data from a region in Chile where residents were inadvertently exposed to high levels of arsenic, a naturally occurring element found in many minerals.

  • Sun Pharma and Ranbaxy Laboratories announced that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of Ranbaxy by Sun Pharma and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).

  • A research consortium headed by Professor Hossam Haick of the Technion-Israel Institute of Technology is developing a product that, when coupled with a smartphone, will be able to screen the user’s breath for early detection of life-threatening diseases.

  • Jamia Islamia Isha Atul Uloom’s Ali Allana College of Pharmacy, Akkalkuwa, Dist. Nandurbar has organized national level workshop on “Industrial and Academic Perspectives of Regulatory Affairs in pharmaceutical industry.” This will be one day workshop on 10 February 2015 from time 10 am to 4.30 pm.

  • Novartis announced results from the pivotal Phase III clinical trial demonstrating Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy (a procedure to remove blood from the body to reduce the concentration of red blood cells) and reduced spleen size in patients with polycythemia vera (PV) who had an inadequate response to or unacceptable side effects from hydroxyurea as defined according to the modified European LeukemiaNet (ELN) criteria, which is published in The New England Journal of Medicine (NEJM). In PV, hematocrit control and spleen size reduction are key measures of a patient's response to therapy.

  • Scientists have discovered the unconventional way the cholera bacterium stabs and kills other bacteria to steal their DNA, making it potentially more virulent. Cholera is caused when the bacterium Vibrio cholerae (V cholerae) infects the small intestine. The disease is characterised by acute watery diarrhea resulting in severe dehydration.

Subscribe to Pharma News